Nuveen
DMAC icon

Nuveen’s DiaMedica Therapeutics DMAC Stock Holding History

Nuveen’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Sell
48,349
-30,761
-39% -$189K ﹤0.01% 3457
2026
Q1 		$536K Sell
79,110
-31,918
-29% -$253K ﹤0.01% 2815
2025
Q4 		$884K Buy
111,028
+36,361
+49% +$272K ﹤0.01% 2669
2025
Q3 		$513K Buy
74,667
+40,320
+117% +$219K ﹤0.01% 2881
2025
Q2 		$134K Buy
+34,347
New +$134K ﹤0.01% 3226

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's DMAC Position: Q2 2026 in Review

Nuveen reduced its DiaMedica Therapeutics (DMAC) stake by 39% in Q2 2026, selling an estimated $189K and leaving 48,349 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #3457.

Nuveen first reported a position in DMAC in Q2 2025 and has held it in 5 quarters since. The position peaked at $884K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Nuveen held 48,349 shares of DiaMedica Therapeutics worth $340K as of Q2 2026.
  • Nuveen sold 30,761 DiaMedica Therapeutics shares in Q2 2026, an estimated $189K.
  • DiaMedica Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3457 holding.
  • Nuveen first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Nuveen's DiaMedica Therapeutics position peaked at $884K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.